Australia markets closed

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.3400+0.1400 (+6.36%)
At close: 04:00PM EDT
2.3100 -0.03 (-1.28%)
After hours: 07:10PM EDT

Gamida Cell Ltd.

5 Nahum Heftsadie Street
Givaat Shaul
Jerusalem 91340
Israel
972 2 659 5666
https://www.gamida-cell.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 166

Key executives

NameTitlePayExercisedYear born
Dr. Julian Adams Ph.D.CEO & Director707kN/A1955
Mr. Shai Lankry CPA, M.B.A.Chief Financial Officer564kN/A1976
Ms. Michele Ilene Korfin M.B.A., R.Ph.Chief Operating & Chief Commercial Officer510kN/A1972
Dr. Ronit Simantov M.D.Chief Medical & Chief Scientific Officer581kN/A1965
Dr. Jas UppalChief Regulatory & Quality Officer476kN/A1968
Mr. Joshua F. PattersonGen. Counsel & Chief Compliance OfficerN/AN/A1976
Mr. Paul NeeVP of MarketingN/AN/AN/A
Mr. Naftali Brikashvili CPASr. VP Fin. & OperationsN/AN/AN/A
Dr. Tracey Lodie Ph.D.Scientific Advisor & ConsultantN/AN/A1971
Mr. Vladimir MelnikovSr. VP of Global Operations & ManufacturingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Corporate governance

Gamida Cell Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.